Anglo-Swedish pharma major AstraZeneca (LSE: AZN) this morning reported first-quarter 2015 financials, showing that total revenue (defined as product sales and externalization revenue) grew by 1% at constant exchange rates to $6.06 billion, although down 6% as reported, but beating the forecast of $5.98 billion from analysts polled by Thomson Reuters.
Core net profit fell 7% to $1.37 billion. Core earnings per share (EPS) declined by 3% to $1.08, just ahead of analysts’ consensus expectations of $1.07).Reported operating profit grew by 15% to $933 million. AstraZeneca’s shares dipped 2.3% to £47.03 in early trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze